Patients are at the heart of our R&D strategy. We engage with patients at every step, including mapping patient journeys, developing patient-reported outcomes, and providing patient samples.

Here also lies the responsibility for leading the clinical science through robust trial methodology, novel endpoints, and understanding regulator, payor, physician and patient needs.

We build on our extensive experience in NCE research with proprietary chemistry to invent valuable chemical matter. Our treatments are developed with both symptomatic as well as disease-modifying potential.

We drive external innovation to add to our existing treatment portfolio and enter into new modalities (e.g. biologics). We are leading the science through collaboration (e.g. 23andMe) and building networks (e.g. human tissue network) to further scientific breakthroughs.